Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Clinical characteristics of the first cohort (N = 134)

From: Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort

Characteristic Patients with MDD (N = 85) Healthy participants (N = 49)
Female:Male, N (%) 50:35 (59 %:41 %) 32:17 (65 %:35 %)
Age in years, mean (SD), range 36.1 (12.5), 19–61 32.5 (10.2), 20–57
Ethnicitya, N (%)   
Aboriginal 0 0
Arab 3 (4 %) 1 (2 %)
Asian 9 (11 %) 9 (18 %)
Black 1 (1 %) 0
Latin American/Hispanic 5 (6 %) 2 (4 %)
White 59 (69 %) 35 (71 %)
Other 5 (6 %) 2 (4 %)
Mixed 3 (4 %) 0
Marital status, N (%)   
Never Married 48 (57 %) 26 (53 %)
Separated 7 (8 %) 1 (2 %)
Married 16 (19 %) 12 (25 %)
Divorced 7 (8 %) 3 (6 %)
Domestic Partnership 5 (6 %) 6 (12 %)
Widowed 2 (2 %) 1 (2 %)
Occupational status, N (%)   
Working now 45 (53 %) 28 (57 %)
Disabled (permanent or temporary) 13 (7 %) 0
Temporary leave 5 (3 %) 0
Looking, unemployed 10 (5 %) 3 (6 %)
Student 8 (4 %) 15 (31 %)
Retired 1 (1 %) 0
If employed, number of hours scheduled to work over the past 2 weeks: mean (SD) 50.0 (27.2) 53.8 (25.8)
If employed, number of hours missed due to symptoms over the past 2 weeks: mean (SD) 10.5 (18.2) 0.1 (0.6)
Education, years: mean (SD) 14.1 (2.0) 15.9 (2.9)
Age of onset of MDD, years:   
mean (SD), range 20.6 (10.7), 5–55 n/a
Single episode:Recurrent, N (%) 24:61 (29 %:71 %) n/a
No. previous episodes, mean (SD) 4.3 (2.8) n/a
Current episode duration   
≤12 months 39 (46 %) n/a
1–2 years 13 (15 %)  
>2 years 30 (35 %)  
Unknown/not reported 3 (4 %)  
Median duration (range), months 14.5 (3–151)  
Comorbiditiesb,c   
Substance-Related Disorders 7 (8 %) n/a
Anxiety Disorders 67 (79 %)  
Eating Disorders 1 (1 %)  
Stable medical conditions 52 (61 %)  
Use of antidepressants during current   
episode, N (%) 60 (71 %) n/a
No. antidepressants used, mean (SD) 1.7 (1.5)  
Baseline MADRS, mean (SD) 29.9 (6.0) 0.4 (1.0)
Baseline YMRS, mean (SD) 2.2 (1.8) 0.3 (0.7)
Baseline CGI Severity, mean (SD) 4.7 (0.8) 1.0 (0.0)
Baseline QIDS-SR, mean (SD) 15.9 (4.3) 2.1 (1.7)
Baseline SDS, mean (SD) 16.6 (7.5) 0.0 (0.0)
Baseline LEAPS, mean (SD) 14.1 (6.1) 1.9 (2.7)
  1. aCategories adapted from ethnic-origin groups listed in national census questionnaires [67]
  2. bBased on DSM-IV-TR, as determined by the Mini International Neuropsychiatric Interview
  3. cPercentages may not add up to 100 % because patients may have more than 1 comorbid condition
  4. MDD Major depressive disorder, SD Standard deviation, MADRS Montgomery Åsberg Depression Rating Scale, YMRS Young Mania Rating Scale, CGI Clinical Global Impression, QIDS-SR Quick Inventory of Depressive Symptomatology, Self-Report, SDS Sheehan Disability Scale, LEAPS Lam Employment Absence and Productivity Scale